GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Siemens Healthineers forecasts slower 2027 growth as China weakness persists - Finance news and analysis from Global Banking & Finance Review
Finance

Siemens Healthineers forecasts slower 2027 growth as China weakness persists

Published by Global Banking & Finance Review

Posted on November 5, 2026

2 min read

· Last updated: November 5, 2026

Add as preferred source on Google

Siemens Healthineers Foresees Slowed 2027 Growth Amid China Market Challenges

Siemens Healthineers 2027 Financial Outlook and Market Performance

By Kira Britten and Paolo Laudani

Growth Forecasts and Analyst Expectations

Nov 5 - German medical technology company Siemens Healthineers forecast slower-than-expected growth in fiscal 2027 on Thursday after weakness in China continued to weigh on its diagnostics business.

The company expects fiscal 2027 comparable revenue growth of 4%-5%, below analyst expectations of 5.5%.

It forecast adjusted earnings per share of 2.20 euros to 2.40 euros, compared with analyst expectations of 2.37 euros and fiscal 2026 adjusted EPS of 2.42 euros.

Fourth-Quarter Financial Highlights

  • Fourth-quarter adjusted EBIT fell 2.0% to 1.077 billion euros from 1.098 billion euros a year earlier
  • Fourth-quarter revenue rose 7.3% to 6.784 billion euros from 6.322 billion euros a year earlier
  • Fourth-quarter diagnostics revenue fell 4.2% on a comparable basis to 1.067 billion euros
Regional and Market-Specific Challenges
  • Weakness in China remained a challenge, with diagnostics revenue in the region hurt by structural changes in the market environment
  • China accounts for about 10% of group revenue and is Siemens Healthineers' second-largest market after the US

Corporate Developments and Shareholder Actions

  • The German company will change its name to Healthineers as part of its planned spin-off from Siemens, which shareholders are due to vote on in February 2027
  • Shares were seen down about 5% in pre-market trading

Additional Information

($1 = 0.8880 euros)

(Reporting by Kira Britten and Paolo Laudani, editing by Matt Scuffham)

Key Takeaways

  • FY2027 comparable revenue growth forecasted at 4%–5%, below analyst expectations (~5.5%) due to China diagnostics weakness (kwsn.com)
  • Q4 results: revenue rose 7.3% to €6.784 bn; adjusted EBIT fell 2% to €1.077 bn; diagnostics segment revenue dropped 4.2% (kwsn.com)
  • China remains a drag — diagnostics market structure shift hurting segment; China is ~10% of group revenue and second-largest market after U.S. (kwsn.com)
  • Mid‑term strategy (FY2027–30) targets higher growth: Imaging & Precision Therapy 6–9% annually, group 5–7%, with diagnostics rebounding to mid‑single‑digit growth (siemens-healthineers.com)
  • Diagnostics spin‑off planned: company will drop “Siemens” and rename to Healthineers; shareholders vote in Feb 2027 (kwsn.com)

Frequently Asked Questions

How much revenue growth is Siemens Healthineers projecting for 2027?
The company expects comparable revenue growth of 4% to 5% in fiscal 2027, below analyst expectations of 5.5%.
What impact did China have on Siemens Healthineers’ latest financial results?
Diagnostics revenue in China fell 4.2% year-on-year, with the region’s market changes negatively affecting overall group earnings.
Will Siemens Healthineers change its name in the future?
Yes, the company plans to change its name to Healthineers following a spin-off from Siemens, pending a shareholder vote in February 2027.
What are Siemens Healthineers’ 2027 earnings per share projections?
Adjusted earnings per share are forecast between 2.20 euros and 2.40 euros in 2027, compared to analyst expectations of 2.37 euros.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category